

The Trendlines Group

Financial Highlights Q1 2018

Steve Rhodes
Chairman and CEO

Todd Dollinger
Chairman and CEO

Gabi Heller
Chief Financial Officer

May 2018

Agenda

- Corporate highlights
- Financial highlights
- Post Q1 2018 developments

Legal disclaimer

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. (“Company”) or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.




Corporate highlights

10 years of portfolio value expansion

US\$ millions

Portfolio value with exit proceeds




*Portfolio value includes the fair value of investments in portfolio companies accounted for under the equity method or consolidated subsidiaries

Key financial developments Q1 2018

	31 March 2018	31 December 2017	Change	% Change
Portfolio value	US\$ 97.4 million	US\$ 96.8 million	+ US\$ 0.6 million	+0.6%
Book value	US\$ 91.5 million	US\$ 92.9 million	- US\$ 1.4 million	-1.5%
Current assets	US\$ 18 million	US\$ 20.4 million	- US\$ 2.4 million	-12%
	31 March 2018	31 March 2017	Change	% Change
Total expenses	US\$ 1.9 million	US\$ 2.6 million	- US\$ 0.7 million	-25%
Net loss	(US\$ 1.4 million)	(US\$ 1.6 million)	+ US\$ 0.2 million	+13%

Focus on cash flow

Total Cash from Operations
(US\$ millions)



Q1 2018 developments

- Trendlines Medical Singapore Pte. Ltd. and K2 Global Pte. Ltd. to participate in the Singapore government's SGD100 million SPRING SEEDS Capital start-up investment program
- Trendlines and Nutreco Investments B.V. signed collaboration MOU
- One new medical portfolio company established in Israel
- Fourteen portfolio companies are in the commercialization stage
- Cost-reduction program for 2018 showing significant results – expenses reduced by approximately 25% compared to Q1 2017

10 companies (+1) to watch*

- ApiFix Ltd.
- BioFishency Ltd.
- EdenShield Ltd.
- Fidmi Medical Ltd.
- Gordian Surgical Ltd.
- Leviticus Cardio Ltd.
- MemTech Ltd.
- Saturas Ltd.
- STS Medical Ltd.
- Vensica Medical Ltd.

+1 Stimatix GI Ltd.



*Updated report issued: [23 April 2018](#)

Q1 highlights from the “10 Companies to Watch” report

- ApiFix Ltd. and Gordian Surgical Ltd. completed >200 surgeries
- BioFishency Ltd. reached US\$800,000 in sales in Q1 2018
- EdenShield Ltd. increased installations 3X in Q1 2018
- Leviticus Cardio Ltd. announced animal trial with successful 60+ day follow-up
- Saturas Ltd. completed US\$4 million investment round
- STS Medical Ltd. preparing manufacturing capabilities for U.S. and Israeli markets




Financial highlights

Consolidated condensed report of income

	Group		
	Three Months Ended		
	31 March 2018 (Unaudited) US\$'000	31 March 2017 (Unaudited) US\$'000	Change %
<u>Income:</u>			
Loss from change in fair value of investments in Portfolio Companies	(1,234)	(738)	67.21
Income from services to Portfolio Companies	1,440	1,085	32.72
Group's share of losses of companies accounted for under the equity method	-	(73)	<i>n.m.</i>
Income from contracted R&D services	89	131	(32.06)
Financial income	-	670	<i>n.m.</i>
Other income	275	106	159.43
<u>Total income</u>	<u>570</u>	<u>1,181</u>	<u>(51.74)</u>
<u>Expenses</u>			
Operating, general and administrative expenses	1,507	2,203	(31.59)
Marketing expenses	95	81	17.28
R&D expenses, net	247	298	(17.11)
Financial expenses	70	-	<i>n.m.</i>
<u>Total expenses</u>	<u>1,919</u>	<u>2,582</u>	<u>(25.68)</u>
Loss before income taxes	(1,349)	(1,401)	(3.71)
Income tax expenses	2	226	(99.11)
<u>Net loss</u>	<u>(1,351)</u>	<u>(1,627)</u>	<u>(16.96)</u>

Key value components



* Israeli government loans are non-recourse loans which only come due upon exit events.

** Deferred taxes from unrealized portfolio company valuation profits are offset and paid only upon realization of cash from exits.



Post Q1 2018 developments

Post Q1 2018 developments

- Disclosure of Stimatix GI Ltd. as Most Valuable Portfolio Company (“MVP”) and acquirer as B. Braun Medical SAS
- ElastiMed Ltd. received approval of US\$1.6 million grant from Horizon 2020 program
- Over 500 people attended the AgriVest 2018 conference



MIXii Biomed 2018



MIXiii BIOMED

15 -17 May 2018 | Tel Aviv, Israel

<http://kenes-exhibitions.com/biomed/>





Creating and developing companies to improve the human condition

SGX: 42T
OTCQX: TRNLY

+972.72.260.7000
www.trendlines.com



Steve Rhodes, Chairman & CEO
steve@trendlines.com

Todd Dollinger, Chairman & CEO
todd@trendlines.com

Gabi Heller, Chief Financial Officer
gabi@trendlines.com

10 May 2018